# Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Study · id `cardio:ct-nct01914432` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01914432](<https://clinicaltrials.gov/study/NCT01914432>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01914432

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

## Technical summary

Registry record NCT01914432. Randomized; quadruple masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2014-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 210 participants (enrolled count; ClinicalTrials.gov record NCT01914432, source copy `cardio:ctgov-nct01914432-2014-07-08`, retrieved 2026-10-26)
- Start date: 2013-11 (registry gives no type) (ClinicalTrials.gov record NCT01914432, source copy `cardio:ctgov-nct01914432-2014-07-08`, retrieved 2026-10-26)
- Primary completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01914432, source copy `cardio:ctgov-nct01914432-2014-07-08`, retrieved 2026-10-26)
- Completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01914432, source copy `cardio:ctgov-nct01914432-2014-07-08`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01914432, source copy `cardio:ctgov-nct01914432-2014-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01914432-2014-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia
- Condition: Hyperlipidemia
- Condition: Hypertension
- Intervention (Drug): YH16410
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Telmisartan
- Intervention (Drug): YH16410 placebo
- Intervention (Drug): Rosuvastatin placebo
- Intervention (Drug): Telmisartan placebo
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention name matches this record: Telmisartan (`cardio:telmisartan`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study (`cardio:pubmed-29673890`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7fb0c53a4db3ae434078e6f496b64957298730430280456582ff4c2d84637777
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
